Pulmonary sarcomatoid_MEDI4736+Treme

NCT03022500 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC

Interventions

DRUG: durvalumab + tremelimumab

Sponsor

Seoul National University Hospital